AZITHROMYCIN: MODERN PLACE OF THE DRUG IN THERAPY OF LOWER RESPIRATORY TRACTS INFECTIONS
https://doi.org/10.21518/2079-701X-2017-18-90-94
Abstract
One of the important problems in pulmonology – lower respiratory tract infections that occupy a significant place in the structure of the pulmonary pathology. The major nosological entities at which this infection is the leading or the major ethiologic factor of the lower respiratory tract lesion is community-acquired pneumonia, exacerbations of the chronic obstructive lung disease, chronic bronchitis. The armamentarium of antibacterial drugs used for therapy of the lower respiratory tract infections azithromycin invariably retains leading positions. Depending on the nosological form it is used as the first line drug, an alternative drug or in a combination with other antibiotics. This is preconditioned by a number of exclusive peculiarities of azithromycin that makes it standing apart among other antibacterial drugs.
About the Authors
S. I. Sazhnova
MD Razumovsky Saratov State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
N. A. Karoli
MD Razumovsky Saratov State Medical University of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
A. P. Rebrov
MD Razumovsky Saratov State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Дворецкий Л.И. Азитромицин в лечении инфекций дыхательных путей. Позиции сохраняются. РМЖ, 2004, 2: 83-87.
2. Утешев Д.Б., Крылов И.А., Буюклинская О.В. Азитромицин: респираторная специфика и уникальность. Лечебное дело, 2008, 1: 15-18.
3. Yamaya M, Azuma A, Takizawa H et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J, 2012, 40: 485-494.
4. Кароли Н.А., Архангельская Е.Е., Ребров А.П. Азитромицин в лечении инфекций дыхательных путей. Consilium Medicum, 2014, 3: 48-54.
5. Моисеев С.В. Азитромицин в лечении внебольничной пневмонии. Клиническая фармакология и терапия, 2006, 15(2): 32-36.
6. Фомина И.П., Ушкалова Е.А. Применение азитромицина для лечения внебольничных пневмоний у взрослых и детей. Фарматека, 2002, 11: 3-4.
7. Смоленов И.В., Красильникова А.В. Фармакоэкономические аспекты применения азитромицина различных производите-лей при внебольничной пневмонии у взрослых. Фарматека, 2003, 13: 1-7.
8. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. ERJ, 2007, 29: 1224-1238.
9. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2016: 111.
10. Kim N, Leeper KV Jr. Epidemiology of chronic bronchitis and acute infective exacer-bations of chronic bronchitis. Semin Respir Crit Care Med, 2000, 21(2): 73-8.
11. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med, 2005, 165: 891–7.
12. Bach PB, Brown C, Gelfand SE. et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med, 2001, 134: 600–620.
13. McCrory DC, Brown C, Gelfand SE. et al. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest, 2001, 119: 1190–209.
14. Синопальников А.И., Андреева И.В., Стецюк О.У. Безопасность макролидных антибиотиков: критический анализ. Клиническая медицина, 2012, 90(3): 23-30.
15. Кароли Н.А., Ребров А.П. Некоторые аспекты патогенеза и профилактики внезапной сердечной смерти у пациентов с хронической обструктивной болезнью легких. Терапия, 2016, 4: 92-101.
Review
For citations:
Sazhnova SI, Karoli NA, Rebrov AP. AZITHROMYCIN: MODERN PLACE OF THE DRUG IN THERAPY OF LOWER RESPIRATORY TRACTS INFECTIONS. Meditsinskiy sovet = Medical Council. 2017;(18):90-94. (In Russ.) https://doi.org/10.21518/2079-701X-2017-18-90-94
Views:
695
Email this article 